AcelRx provides revise on Zalviso AcelRx Pharmaceuticals.

As reflected in the minutes, the Division restated at the meeting a request for clinical data to check other data AcelRx has developed to assess the efficiency of the Zalviso device. Related StoriesGlan Clwyd Medical center N Wales spend money on Esaote's G-Scan MRI device for weight-bearing scanningLoyola Medication, Palos Community Medical center jointly launch innovative telemedicine programChildren's Memorial Hermann Medical center offers Halloween safety tipsThe company is likely to submit a process to the Division for a clinical research in post-operative patients designed to measure the effectiveness of adjustments made to enhance product performance.Endometrial hyperplasia was confirmed in two ladies in the higher-dosage lasofoxifene group, three women in the lower-dose lasofoxifene group, no women in the placebo group. Adverse and Safety Events No significant difference in the death rate was observed between your higher-dosage lasofoxifene group and the placebo group . However, there have been 65 deaths in the placebo group and 90 deaths in the lower-dose lasofoxifene group . A trend toward more deaths due to cancers in the lower-dosage lasofoxifene group was near however, not significant ; the maximum number of fatal cancers at specific anatomical sites in the lasofoxifene organizations versus the placebo group was three. In the higher-dosage lasofoxifene group, there have been 73 deaths from all causes and 25 deaths because of cancer ; neither rate was significantly not the same as that in the placebo group .